CCLA Investment Management Acquires 229,199 Shares of Avantor, Inc. (NYSE:AVTR)

CCLA Investment Management lifted its holdings in Avantor, Inc. (NYSE:AVTR) by 4.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 5,357,703 shares of the company’s stock after acquiring an additional 229,199 shares during the quarter. Avantor accounts for about 1.8% of CCLA Investment Management’s holdings, making the stock its 29th biggest holding. CCLA Investment Management owned approximately 0.79% of Avantor worth $112,940,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. UMB Bank n.a. bought a new position in Avantor during the 3rd quarter valued at approximately $49,000. Nisa Investment Advisors LLC boosted its stake in shares of Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock valued at $53,000 after purchasing an additional 835 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Avantor by 89.9% during the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after buying an additional 1,285 shares during the period. Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in Avantor by 278.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock worth $130,000 after buying an additional 3,700 shares during the period. Finally, Quarry LP boosted its position in Avantor by 4,489.1% during the 2nd quarter. Quarry LP now owns 6,333 shares of the company’s stock valued at $134,000 after acquiring an additional 6,195 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Price Performance

NYSE AVTR opened at $21.71 on Wednesday. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. Avantor, Inc. has a 12 month low of $19.59 and a 12 month high of $28.00. The stock has a market cap of $14.78 billion, a price-to-earnings ratio of 47.20, a PEG ratio of 2.75 and a beta of 1.28. The company’s 50 day moving average is $21.49 and its two-hundred day moving average is $23.36.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Avantor in a research report on Thursday, September 26th. Wells Fargo & Company cut their price target on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, October 28th. Barclays lowered their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Robert W. Baird reduced their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Finally, UBS Group lowered their price objective on Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, October 8th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.69.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.